Maria Angeles Martínez

Maria Angeles Martínez

Auto-generated profile, based on publicly available information

Maria Angeles Martínez

Immunology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Medicine
Verified
Journal Article
Closed access
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
MLMoisés Labrador-Horrillo
Moisés Labrador-Horrillo
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
MMMaria Angeles Martínez
Maria Angeles Martínez
XMXavier Martínez-Gómez
Xavier Martínez-Gómez
MVMiquel Vilardell-Tarrés
Miquel Vilardell-Tarrés
A new autoantibody against a 155-kDa protein has been described in patients with myositis. We conducted a study to determine the occurrence and types of cancer occurring in a cohort of patients with polymyositis (PM) or dermatomyositis (DM) and analyzed the value of this autoantibody as a serologic marker of cancer-associated myositis (CAM). Serum samples from all patients were examined by protein immunoprecipitation assays with HeLa cells to determine the presence of a 155-kDa protein band. HLA-DRB1 and DQA1 typing was performed by polymerase chain reaction-reverse sequence specific oligonucleotide. Statistical analyses were carried out with the Mann Whitney U and Fisher exact tests. Associations were determined using odds ratios (ORs) with 95% confidence intervals (CI). Eighty-five patients with myositis (20 PM and 65 DM) were included. CAM was detected in 16 patients (19%), 14 with DM. The shawl sign rash was significantly more frequent in patients with CAM than in those without (p < 0.01). Adenocarcinoma was the most frequent type of cancer (87.5%). Anti-p155 autoantibody was found in 1 of the 20 (5%) patients with PM and in 15 of the 65 (23%) patients with DM. A relationship between anti-p155 and CAM was found in DM patients (OR, 23; 95% CI, 5.23-101.2). The HLA-DQA1*0102 allele was not found in any of the anti-p155-positive patients. The prevalence of CAM in our cohort was 19%. Autoantibody against p155 was highly related to CAM and could be a reliable marker of cancer in patients with DM. Abbreviations CAM = cancer-associated myositis, CI = confidence interval, DM = dermatomyositis, OR = odds ratio, PM = polymyositis.

1 June 2012 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MLMoises Labrador-Horrillo
Moises Labrador-Horrillo
MMMaria Angeles Martínez
Maria Angeles Martínez
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
EBEva Balada
Eva Balada
CJCandido Juarez
Candido Juarez
Background A new myositis-specific autoantibody (anti-p155) directed against transcriptional intermediary factor 1 γ (TIF1γ) has been described as a good marker of cancer-associated myositis (CAM). Objective To analyse the feasibility of detecting this autoantibody in patient serum samples using new assays with commercially available recombinant TIF1γ. Methods The study included 90 Spanish patients with dermatomyositis (DM), classified as clinically amyopathic DM, CAM, or DM without cancer. Anti-TIF1γ antibodies were detected by ELISA and immunoblot techniques and compared with anti-p155 antibody detection by protein immunoprecipitation assays with radiolabelled HeLa cells. The κ coefficient was used to compare the agreement between the different tests. Results Serum samples from 23 (25.6%) and 20 (22.2%) patients with DM recognised TIF1γ by ELISA and immunoblot, respectively. ELISA (κ=0.91) and immunoblot (κ=0.88) showed excellent agreement with immunoprecipitation analysis (anti-p155). Good concordance (κ=0.91) was also seen between ELISA and immunoblot. Conclusions Excellent agreement was found between anti-p155 detected by immunoprecipitation and anti-TIF1γ detected by ELISA or immunoblot. These data indicate that identification of this autoantibody can be reliably performed in a standard laboratory setting, with potential application in clinical practice for cancer screening in adult patients with DM.

1 February 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AMAnaís Mariscal
Anaís Mariscal
MMMilena Milán
Milena Milán
ABAndrés Baucells
Andrés Baucells
MMMaria Angeles Martínez
Maria Angeles Martínez
AGAndrea Garcia Guillen
Andrea Garcia Guillen
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
Objectives: Anti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1γ. Methods: We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebrón Hospital (Barcelona, Spain) tested for anti-TIF-1γ autoantibodies using the Euroline profile and an in-house immunoblot assay. Results: A total of 27 anti-TIF-1γ were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen’s kappa 0.3163. Expected prevalence of anti-TIF-1γ autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1γ autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1γ antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion: We recommend using a second validated method to confirm Euroline-detected anti-TIF-1γ antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1γ antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ABAndrés Baucells
Andrés Baucells
MMMaria Angeles Martínez
Maria Angeles Martínez
MAMarcelo Alvarado-Cardenas
Marcelo Alvarado-Cardenas
AMAnaís Mariscal
Anaís Mariscal
LMLaura Martinez-Martinez
Laura Martinez-Martinez
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
A distinctive new indirect immunofluorescence pattern in liver tissue has been associated with anti‐HMGCR autoantibodies. It is known as HALIP (HMGCR Associated Liver Immunofluorescence Pattern). In this study, we furthered the original studies to demonstrate the association of anti‐HMGCR antibodies with the HALIP. Human anti‐HMGCR antibodies from patients’ sera were purified and incubated with rat triple tissue (kidney/stomach/liver). A characteristic HALIP was observed. Additionally, a colocalization assay of human anti‐HMGCR antibodies with rabbit polyclonal anti‐HMGCR antibodies showed colocalization of both immunofluorescence patterns. This study confirms that the HALIP is due to human anti‐HMGCR antibodies.